Cyberknife treatment for nonsmall cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2014.02.009

Abstract

Abstract: Surgery is the main treatment means for early stage nonsmall cell lung cancer (NSCLC), radiotherapy is the alternative choice for the patient who has surgical contraindications or rejects operation. Cyberknife is a new stereotactic radiotherapy, which has two functions: radiosurgery and radiotherapy. Cyberknife has a remarkable clinical result in the treatment of NSCLC by using realtime image guidance system and breathing tracking system to provide highdose and highprecision irradiation.

Key words: Carcinoma, non-small-cell lung, Radiotherapy, Radiosurgery

Yu Xiao, Wang Yanming. Cyberknife treatment for nonsmall cell lung cancer[J]. Journal of International Oncology, 2014, 41(2): 107-109.

References

［1］ Seisen T, Drouin SJ, Phé V, et al. Current role of imageguided robotic radiosurgery (Cyberknife()） for prostate cancer treatment［J］. BJU Int, 2013, 111(5)： 761-766. ［2］ Bibault JE, Prevost B, Dansin E, et al. Imageguided robotic stereotactic radiation therapy with fiducialfree tumor tracking for lung cancer［J］. Radiat Oncol, 2012, 7： 102. ［3］ Onishi H, Araki T. Stereotactic body radiation therapy for stage Ⅰ nonsmallcell lung cancer: a historical overview of clinical studies［J］. Jpn J Clin Oncol, 2013, 43(4)： 345-350. ［4］ Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage Ⅰ nonsmall cell lung cancer: updated results of 257 patients in a Japanese multiinstitutional study［J］. J Thorac Oncol, 2007, 2(7 Suppl 3)： S94-100. ［5］ van Baardwijk A, Tomé WA, van Elmpt W, et al. Is highdose stereotactic body radiotherapy (SBRT) for stage Ⅰ nonsmall cell lung cancer (NSCLC) overkill? A systematic review［J］. Radiother Oncol, 2012, 105(2)： 145-149. ［6］ Guckenberger M, Wulf J, Mueller G, et al. Doseresponse relationship for imageguided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation［J］. Int J Radiat Oncol Biol Phys, 2009, 74(1)： 47-54. ［7］ Zimmermann F, Wulf J, Lax I, et al. Stereotactic body radiation therapy for early nonsmall cell lung cancer［J］. Front Radiat Ther Oncol, 2010, 42： 94-114. ［8］ Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase Ⅱ trial of medically inoperable stage Ⅰ nonsmallcell lung cancer patients treated with stereotactic body radiotherapy［J］. J Clin Oncol, 2009, 27(20)： 3290-3296. ［9］ Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage Ⅰ nonsmallcell lung cancer: can SBRT be comparable to surgery?［J］. Int J Radiat Oncol Biol Phys, 2011, 81(5)： 13521358. ［10］ van der Voort van Zyp NC, Prévost JB, Hoogeman MS, et al. Stereotactic radiotherapy with realtime tumor tracking for nonsmall cell lung cancer: clinical outcome［J］. Radiother Oncol, 2009, 91(3)： 296-300. ［11］ Bonnette P. Chemoradiotherapy before surgery in stage Ⅲ nonsmallcell lung cancer［J］. Rev Mal Respir, 2013, 30(2)： 105-114. ［12］ Takeda A, Sanuki N, Kunieda E, et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm［J］. Int J Radiat Oncol Biol Phys, 2009, 73(2)： 442-448. ［13］ Whyte RI. Stereotactic radiosurgery for lung tumors［J］. Semin Thorac Cardiovasc Surg, 2010, 22(1)： 59-66. ［14］ Pennathur A, Abbas G, Schuchert MJ, et al. Imageguided radiofrequency ablation for the treatment of earlystage nonsmall cell lung neoplasm in highrisk patients［J］. Semin Thorac Cardiovasc Surg, 2010, 22(1)： 53-58. ［15］ Brown WT, Wu X, Fayad F, et al. Application of robotic stereotactic radiotherapy to peripheral stage Ⅰ nonsmall cell lung cancer with curative intent［J］. Clin Oncol (R Coll Radiol), 2009, 21(8)： 623-631. ［16］ Chi A, Liao Z, Nguyen NP, et al. Systemic review of the patterns of failure following stereotactic body radiation therapy in earlystage nonsmallcell lung cancer: clinical implications［J］. Radiother Oncol, 2010, 94(1)： 1-11. ［17］ Reck M, Heigener DF, Mok T, et al. Management of nonsmallcell lung cancer: recent developments［J］. Lancet, 2013, 382(9893)： 709-719. ［18］ Saadeddin A. Radiotherapy for NSCLC: review of conventional and new treatment techniques［J］. J Infect Public Health, 2012, 5 Suppl 1： S45-49. ［19］ Dieterich S, Pawlicki T. Cyberknife imageguided delivery and quality assurance［J］. Int J Radiat Oncol Biol Phys, 2008, 71(1 Suppl)：S126-130. ［20］ Lartigau E， Mirabel X， Prevost B， et al． Extracranial stereotactic radiotherapy: preliminary results with the CyberKnife［J］. Onkologie, 2009, 32(4)： 209-215. ［21］ Prevost JB, Voet P, Hoogeman M, et al. Fourdimensional stereotactic radiotherapy for early stage nonsmall cell lung cancer: a comparative planningstudy［J］. Technol Cancer Res Treat, 2008, 7(1)： 27-33. ［22］ Murphy MJ. Intrafraction geometric uncertainties in frameless imageguided radiosurgery［J］. Int J Radiat Oncol Biol Phys， 2009, 73(5)： 1364-1368. ［23］ McCammon R, Schefter TE, Gaspar LE, et al. Observation of a dosecontrolrelationship for lung and liver tumors after stereotactic body radiation therapy［J］. Int J Radiat Oncol Biol Phys, 2009, 73(1)： 112-118.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[5]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[6]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[7]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[8]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[9]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[10]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[11]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[12]	Shi Xaioqi, Wang Hongyan. Research progress on the interaction between gut microbiota and radiation enteritis [J]. Journal of International Oncology, 2023, 50(4): 244-247.
[13]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun. Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases [J]. Journal of International Oncology, 2023, 50(3): 138-143.
[14]	Huang Huayu, Gong Hongyun, Song Qibin. Influencing factors of pneumonitis in the period of thoracic radiotherapy combined with immunotherapy [J]. Journal of International Oncology, 2023, 50(2): 102-106.
[15]	Cao Xiaohui, Yu Hong, Li Wanhu. Application of CT-based radiomics analysis in predicting and identifying of treatment-associated pneumonitis [J]. Journal of International Oncology, 2023, 50(2): 107-111.